---
title: Predict Parkinson or dementia risk
nct_id: NCT06629207
phase: NA
status: RECRUITING
sponsor: Insel Gruppe AG, University Hospital Bern
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06629207"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06629207"
last_fetched: "2026-05-10T14:08:35.316Z"
source: "Parkinson's Pathways (curated)"
---
# Predict Parkinson or dementia risk

**Goal (in five words):** Predict Parkinson or dementia risk

**Official Title:** Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder

**Trial ID:** [NCT06629207](https://clinicaltrials.gov/study/NCT06629207)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Insel Gruppe AG, University Hospital Bern
- **Target Enrollment:** 20 participants
- **Start Date:** 2024-10-07
- **Completion Date:** 2026-08-01
- **Conditions:** Parkinson Disease, REM Sleep Behavior Disorder, Dementia, Lewy Body
- **Interventions:** PET/CT with 18-FDG, SPECT : 123 I-FP-CIT (DATSCAN), MRI
- **Intervention Types:** DEVICE

## Summary For Families

Goal: to spot which people with idiopathic REM sleep behavior disorder are most likely to develop Parkinson's disease or Lewy body dementia by finding early brain imaging signatures. Approach: participants have FDG-PET to map regional brain glucose metabolism, DAT SPECT with 123I‑FP‑CIT to measure dopamine transporter binding in the nigrostriatal pathway, and MRI for structural detail, then artificial intelligence analyzes those molecular and structural patterns to predict risk; these are diagnostic scans that do not involve drugs or change levodopa treatment. Eligibility: adults 18 and older with a confirmed iRBD diagnosis by movement disorder specialists, no known Parkinson’s or other neurodegenerative disorder, no clear parkinsonism on exam, and no other causes of RBD such as narcolepsy, moderate to severe sleep apnea, or abnormal neurological or MRI findings.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders
2. Written informed consent

Exclusion Criteria:

1. Known diagnosis of PD or other neurodegenerative disorder
2. Unequivocal signs of parkinsonism on examination
3. Narcolepsy or other known causes of RBD
4. Moderate to severe obstructive sleep apnea
5. Abnormal neurological or MRI examination
```

## Locations (1)

- Inselspital, University Clinic for Nuclear Medicine, Bern, Switzerland _(46.9481, 7.4474)_
  - Axel Rominger, Prof. Dr. med. — (CONTACT) — +41 31 632 26 10 — axel.rominger@insel.ch
  - Franziska Strunz, PhD — (CONTACT) — +41 31 66 4 30 22 — studies.nuk@insel.ch

## Central Contacts

- Axel Rominger, Prof. Dr. med. — (CONTACT) — +41 316322610 — axel.rominger@insel.ch
- Franziska Strunz, PhD — (CONTACT) — +41 316643022 — studies.nuk@insel.ch

---

*Canonical: https://parkinsonspathways.com/trial/NCT06629207*  
*HTML version: https://parkinsonspathways.com/trial/NCT06629207*  
*Source data: https://clinicaltrials.gov/study/NCT06629207*